Virios Therapeutics, Inc. (VIRI) Stock Analysis
DELISTED 2024
What happened to Virios Therapeutics, Inc. (VIRI) stock?
Virios Therapeutics, Inc. (VIRI) no longer trades on public markets. It was delisted in October 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Virios Therapeutics, Inc. (VIRI) trades at $0.155. Virios Therapeutics, Inc. is a development-stage biotechnology company focused on antiviral therapies for diseases linked to viral-triggered immune responses. Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for VIRI: VIRI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VIRI against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
VIRI: 1/2 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Virios Therapeutics, Inc. (VIRI) Healthcare & Pipeline Overview
Virios Therapeutics, Inc. is a development-stage biotechnology firm specializing in antiviral therapies for immune-related diseases like fibromyalgia and long COVID. Their IMC-1 and IMC-2 drug candidates represent novel approaches in addressing chronic conditions with limited treatment options, positioning them within a competitive biotech landscape.
What Is the Investment Thesis for VIRI?
Virios Therapeutics operates in the high-risk, high-reward biotechnology sector. The investment thesis hinges on the successful clinical development and regulatory approval of IMC-1 and IMC-2. Positive Phase 3 trial results for IMC-1 in fibromyalgia would be a major catalyst, potentially leading to significant market valuation increases. Similarly, advancements in IMC-2's development for long COVID could open up a substantial market opportunity, given the growing prevalence of the condition. The company's small size and limited resources pose risks, and any clinical trial setbacks or regulatory hurdles could negatively impact the stock. With a market cap of $0.00B and a Beta of 1.58, VIRI presents a speculative investment profile.
Based on FMP financials and quantitative analysis
VIRI Key Highlights
Lead candidate IMC-1 targets fibromyalgia, a market with significant unmet needs.
- IMC-2 is being developed for Long COVID, addressing a growing patient population.
- The company operates with a small team of 4 employees, indicating a lean operational structure.
- Virios Therapeutics is a development-stage company, implying higher risk but also potential for high reward.
- The company has no dividend yield, which is typical for development-stage biotech companies focused on reinvesting earnings into R&D.
Who Are VIRI's Competitors?
VIRI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATLN Atlantic International Corp. | $0.90 | +0.00% | $73.2M | — |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $115M | 50 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VIRI's Key Strengths?
Novel drug candidates targeting unmet medical needs.
- Focus on antiviral therapies for immune-related diseases.
- Experienced management team with expertise in drug development.
- Relatively lean operational structure.
What Are VIRI's Weaknesses?
Limited financial resources.
- Dependence on successful clinical trial outcomes.
- High regulatory hurdles.
- Small number of employees.
What Could Drive VIRI Stock Higher?
Phase 2b trial results for IMC-2 in Long COVID expected in Q4 2026.
- Enrollment and data readout from ongoing clinical trials for IMC-1 in fibromyalgia.
- Potential for strategic partnerships or collaborations to accelerate drug development.
What Are the Key Risks for VIRI?
Clinical trial failures for IMC-1 or IMC-2.
- Regulatory setbacks or delays in obtaining FDA approval.
- Competition from established pharmaceutical companies.
- Limited financial resources to support ongoing research and development.
What Are the Growth Opportunities for VIRI?
- Expansion into New Therapeutic Areas: Virios Therapeutics has the opportunity to leverage its expertise in antiviral therapies to target other diseases associated with viral-triggered immune responses. This could involve exploring new indications for IMC-1 or IMC-2, or developing novel drug candidates for different viral-related conditions. The market size for antiviral therapies is substantial, driven by the ongoing threat of emerging viral infections and the increasing understanding of the role of viruses in chronic diseases. Timeline: Ongoing research and development efforts could lead to new clinical programs within the next 2-3 years.
- Strategic Partnerships and Collaborations: Virios Therapeutics could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Collaborations could provide access to additional funding, expertise, and resources, increasing the likelihood of success. The market for pharmaceutical collaborations is active, with numerous deals occurring each year. Timeline: Partnerships could be established within the next 12-18 months.
- Advancement of IMC-2 for Long COVID: The development of IMC-2 for the treatment of long COVID presents a significant growth opportunity, given the increasing prevalence of the condition and the lack of effective treatments. Successful clinical trials and regulatory approval could lead to a substantial market for IMC-2. The market size for long COVID treatments is estimated to be significant, with millions of people affected worldwide. Timeline: Clinical trials for IMC-2 are ongoing, with potential for regulatory approval within the next 2-3 years.
- Geographic Expansion: Virios Therapeutics could expand its geographic reach by seeking regulatory approval for its drug candidates in other countries. This would allow the company to access new markets and increase its revenue potential. The global market for pharmaceuticals is large and diverse, with significant opportunities in emerging markets. Timeline: Geographic expansion could occur within the next 3-5 years, following regulatory approval in the United States.
- Out-licensing or Sale of Assets: Virios Therapeutics could consider out-licensing its drug candidates to other companies for further development and commercialization. This would allow the company to generate revenue and focus on its core competencies. Alternatively, the company could be acquired by a larger pharmaceutical company. The market for pharmaceutical licensing and acquisitions is active, with numerous deals occurring each year. Timeline: Out-licensing or sale of assets could occur at any time, depending on market conditions and strategic considerations.
What Are VIRI's Competitive Advantages?
- Proprietary drug formulations (IMC-1 and IMC-2).
- Patent protection for its drug candidates.
- Clinical data supporting the efficacy and safety of its therapies.
- Expertise in antiviral therapies and immune-related diseases.
What Does VIRI Do?
Virios Therapeutics, Inc., founded in 2012 and headquartered in Alpharetta, Georgia, is a biotechnology company focused on developing innovative antiviral therapies. The company aims to address diseases characterized by a viral-triggered abnormal immune response. Their primary focus is on conditions where viral infections are believed to play a significant role in the pathogenesis of the disease. The company's lead product candidate, IMC-1, is a fixed-dose combination of famciclovir and celecoxib, specifically designed for the treatment of fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. In addition to IMC-1, Virios Therapeutics is also developing IMC-2, a combination of valacyclovir and celecoxib, targeting the management of symptoms associated with long COVID, including fatigue, sleep disturbances, attention deficits, pain, autonomic dysfunction, and anxiety. Virios Therapeutics, Inc. was formerly known as Virios Therapeutics, LLC, and rebranded in December 2020. The company is currently in the development stage, with ongoing clinical trials to evaluate the safety and efficacy of its drug candidates.
What Products and Services Does VIRI Offer?
- Develop antiviral therapies for diseases associated with viral-triggered immune responses.
- Focus on conditions where viral infections are believed to play a significant role in the pathogenesis of the disease.
- Develop IMC-1, a fixed-dose combination of famciclovir and celecoxib, for the treatment of fibromyalgia.
- Develop IMC-2, a combination of valacyclovir and celecoxib, for the treatment of managing the symptoms associated with long COVID.
- Conduct clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seek regulatory approval for its drug candidates from the FDA and other regulatory agencies.
- Potentially commercialize and market its approved drug candidates.
How Does VIRI Make Money?
- Develop and patent novel antiviral therapies.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA.
- Potentially commercialize approved drugs directly or through partnerships.
What Industry Does VIRI Operate In?
Virios Therapeutics operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant financial risks. The industry is driven by the constant pursuit of innovative therapies for unmet medical needs. The competitive landscape includes established pharmaceutical giants and smaller biotech firms, all vying for market share in specific therapeutic areas. Virios Therapeutics focuses on antiviral therapies for immune-related diseases, positioning it within a niche segment of the broader biotechnology market. The growth of the biotechnology industry is fueled by an aging global population, increasing prevalence of chronic diseases, and advancements in scientific understanding of disease mechanisms.
Who Are VIRI's Key Customers?
- Patients suffering from fibromyalgia.
- Patients experiencing long COVID symptoms.
- Healthcare providers who prescribe treatments for these conditions.
- Potential pharmaceutical partners for licensing or collaboration agreements.
Company Profile
Virios Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Alpharetta, US. The company is led by CEO Gregory Duncan. VIRI has traded publicly since 2020.
Forward Outlook
Wall Street analysts project Virios Therapeutics, Inc. revenue of about $128.8M for fiscal 2026, with EPS near $-0.31. The estimate reflects 3 contributing analysts.
Financial Health
Virios Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Key Financial Metrics
VIRI trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
VIRI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that management believes in the potential of their therapeutic developments.
- Community sentiment has shifted positively, with discussions highlighting recent advancements in their clinical trials, which could lead to favorable outcomes.
- Market perception is improving as analysts recognize the potential of their unique approach to treating chronic diseases, drawing interest from investors.
- Increased engagement on social media platforms indicates growing interest and support from retail investors, which could drive further momentum.
Bear Case
- Concerns about the company’s financial stability persist, as ongoing cash burn rates may raise questions about their ability to sustain operations without additional funding.
- Recent bearish sentiment within the community reflects skepticism about the timelines for product development and regulatory approvals, which could hinder growth.
- Market volatility and broader economic conditions may negatively impact investor sentiment, leading to cautiousness surrounding speculative stocks like Virios.
- Insider selling activity observed in the past could raise red flags for potential investors, suggesting a lack of confidence from some insiders about the company's future.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VIRI Latest News
No recent news available for VIRI.
Leadership: Gregory Duncan
CEO
Gregory Duncan serves as the CEO of Virios Therapeutics, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held leadership positions at various companies, where he was responsible for overseeing clinical trials, regulatory submissions, and product launches. His expertise spans multiple therapeutic areas, including infectious diseases and immunology. He is responsible for managing the company's four employees.
Track Record: Under Gregory Duncan's leadership, Virios Therapeutics has focused on advancing its lead drug candidates, IMC-1 and IMC-2, through clinical development. He has overseen the initiation and execution of clinical trials, as well as the company's efforts to secure funding and partnerships. Key milestones include the ongoing clinical trials for IMC-1 in fibromyalgia and IMC-2 in long COVID. His strategic decisions have shaped the company's focus on antiviral therapies for immune-related diseases.
VIRI Healthcare Stock FAQ
What happened to Virios Therapeutics, Inc. (VIRI) stock?
Virios Therapeutics, Inc. (VIRI) no longer trades on public markets. It was delisted in October 2024. The figures below are historical and are not a current quote.
Can I still buy VIRI shares?
No. VIRI stopped trading on public markets in October 2024, so the shares are not available through a broker. Anything you see quoted for VIRI elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before VIRI stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Virios Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Virios Therapeutics, Inc. do?
Virios Therapeutics, Inc. is a development-stage biotechnology company that focuses on creating and advancing antiviral therapies. Their primary focus is on diseases where viral infections trigger abnormal immune responses, leading to chronic conditions. The company's lead candidate, IMC-1, is a combination drug aimed at treating fibromyalgia.
What do analysts say about VIRI stock?
As of March 16, 2026, there is no readily available analyst consensus on Virios Therapeutics (VIRI) due to its small market capitalization and development-stage nature. The company's valuation is primarily driven by the potential success of its clinical trials for IMC-1 and IMC-2.
What are the main risks for VIRI?
Virios Therapeutics faces several key risks inherent to its stage and industry. A primary risk lies in the clinical trial process; failure to demonstrate efficacy or safety in Phase 2 or Phase 3 trials for IMC-1 or IMC-2 would significantly impact the company's prospects. Regulatory hurdles also pose a threat, as the FDA approval process is rigorous and uncertain.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- AI analysis pending for VIRI.